ASX Share rice
Mon 17 May 2021 - 05:11:am (Sydney)

ANP Share Price

ANTISENSE THERAPEUTICS LIMITEDANPPharmaceuticals, Biotechnology & Life Sciences

ANP Company Information

Name:

Antisense Therapeutics Limited

Sector:

Healthcare

Industry:

Drug Manufacturers-Specialty & Generic

GIC Industry:

Pharmaceuticals

GIC Sub Industry:

Pharmaceuticals

Address:

14 Wallace Avenue Toorak VIC Australia 3142

Phone:

61 3 9827 8999

CEO, MD & Director:

Mr. Mark Diamond B.Sc., M.B.A., BSc, MBA, MAICD

CFO & Joint Company Sec.:

Mr. Phillip Allen Hains

Joint Company Sec.:

Ms. Alicia Mellors

Company Overview:

Antisense Therapeutics Limited, a biopharmaceutical company, engages in the research and development of novel antisense pharmaceuticals in Australia. Its product pipeline comprises ATL1102, an antisense inhibitor of CD49d that has completed Phase IIa for the treatment of multiple sclerosis, Duchennes Muscular Dystrophy, multiple sclerosis, asthma, and other inflammatory indications. The company's product pipeline also includes ATL1103, a second generation antisense drug designed to block growth hormone receptor expression thereby reducing levels of the hormone insulin-like growth factor-I in the blood, as well as to treat diseases associated with excessive growth hormone action that has completed Phase II clinical trial. Antisense Therapeutics Limited is based in Toorak, Australia.

ANP Share Price Information

Shares Issued:

574.06M

Market Capitalisation:

$100.46M

Revenue (TTM):

$538.10K

Revenue Per Share (TTM):

$0

Earnings per Share:

$-0.008

Operating Margin (TTM):

$-7.01

Return On Assets (TTM):

$-0.27

Return On Equity (TTM):

$-0.49

Quarterly Revenue Growth (YOY):

-0.387

Gross Profit(TTM):

$464.63K

Diluted Earnings Per Share (TTM):

$-0.007

ANP CashFlow Statement

CashFlow Date:

2020-06-30

Investments:

$-10,262

Change To Liabilities:

$-259,808

Total Cashflow From Investing Activities:

$-10,262

Net Borrowings:

$-97,894

Net Income:

$-5,908,202

Total Cash From Operating Activities:

$-3,945,358

Depreciation:

$107.60K

Change To Account Receivables:

$-339,765

Sale Purchase Of Stock:

$5.49M

Capital Expenditures:

$10.26K

ANP Income Statement

Income Date:

2020-06-30

Income Before Tax:

$-5,908,200

Net Income:

$-5,908,200

Operating Income:

$-5,924,830

Total Revenue:

$30.53K

ANP Balance Sheet

Balance Sheet Date:

2020-06-30

Total Liabilities:

$821.23K

Total Stockholder Equity:

$4.53M

Other Current Liabilities:

$4.58K

Total Assets:

$5.35M

Common Stock:

$69.15M

Other Current Assets:

$256.92K

Retained Earnings:

$-67,036,940

Cash:

$4.06M

Total Current Liabilities:

$798.54K

Property - Plant & Equipment:

$138.12K

Net Tangible Assets:

$4.53M

Total Current Assets:

$5.21M

Net Receivables:

$689.32K

Short-Term Investments:

$138.12K

Accounts Payable:

$107.87K

Short-Term Investments:

$138.12

Non Current Liabilities Total:

$22.69K

ANP Share Price History

ANP News

26 Nov, 2020
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
11 Jun, 2020
Antisense Therapeutics (ASX:ANP | US OTC:ATHJY), an Australian biopharmaceutical company developing and commercializing antisense pharmaceuticals for unmet need in rare diseases announces a virtual poster presentation on the Muscular Dystrophy Association (MDA) Virtual 2020 Conference website.
28 May, 2020
We can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
21 May, 2020
Antisense Therapeutics ("ANP" or the "Company" ASX:ANP | US OTC:ATHJY) is pleased to advise that the Phase II clinical trial of ANP’s immunomodulatory therapy, ATL1102 for Duchenne Muscular Dystrophy (DMD) has met its primary endpoint confirming the safety and tolerability of ATL1102 for advancement into a potentially pivotal Phase IIb clinical trial.